Skip to main content

Table 3 Conductance catheter derived parameters of right ventricular function in animals subjected to acute pulmonary hypertension

From: Effects of inhaled iloprost on right ventricular contractility, right ventriculo-vascular coupling and ventricular interdependence: a randomized placebo-controlled trial in an experimental model of acute pulmonary hypertension

Parameter Treatment Baseline Pulmonary hypertension
    Pre-inhalation 5 minutes after inhalation
REF (%) Iloprost 62 ± 7 50 ± 8* 53 ± 8*
  Control 54 ± 10 40 ± 11* 37 ± 10*
τ/RR Iloprost 0.08 ± 0.01 0.08 ± 0.01 0.09 ± 0.01
  Control 0.07 ± 0.01 0.07 ± 0.01 0.07 ± 0.01
β (ml-1) Iloprost 0.02 ± 0.01 0.02 ± 0.01 0.02 ± 0.01
  Control 0.02 ± 0.02 0.02 ± 0.01 0.02 ± 0.01
C (ml/mmHg) Iloprost 2.29 ± 0.49 1.28 ± 0.33* 1.89 ± 0.64
  Control 2.11 ± 0.93 1.08 ± 0.33* 1.11 ± 0.33*
Emax/Ea Iloprost 1.12 ± 0.11 1.29 ± 0.29 1.03 ± 0.15
  Control 1.11 ± 0.46 1.01 ± 0.31 0.97 ± 0.33
  1. Values are shown for baseline and in pulmonary hypertension before inhalation and 5 minutes after inhalation of either iloprost or control. For the complete experimental time course, see Additional file 4. Values are expressed as mean ± standard deviation. *P < 0.05 versus baseline; P < 0.05 versus before inhalation; P < 0.05 iloprost versus control (corrected for multiple comparisons). β = chamber stiffness constant of end-diastolic pressure volume relationship; C, pulmonary artery compliance; Emax/Ea, ratio of the slope of the end-systolic pressure-volume relationship to effective pulmonary arterial elastance; REF, right ventricular ejection fraction; τ/RR, time constant of ventricular relaxation, corrected for the RR interval.